
Oasmia Pharmaceutical, an innovation-focused specialty pharmaceutical company, is set to acquire exclusive global development rights for Kazia Therapeutics’ ovarian cancer …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

